In addition, we found that the multi-kinase inhibitor and anti-fibrotic drug nintedanib prevents ECM remodeling and tumor relapse in a syngeneic melanoma model treated with TT and impairs the upregulation of miR-143/-145 in melanoma cells, in part through its inhibitory action on PDGFRβ, which is overexpressed on dedifferentiated melanoma cells. This evidence concerns the gene PDGFRB and neoplasm.